- Small cap Synergy Pharmaceuticals (NASDAQ:SGYP) is up 50% premarket on light volume in response to its announcement of positive results in a Phase 3 clinical trial evaluating plecanatide for the treatment of patients with chronic ideopathic constipation (CIC).
- Preliminary analysis shows that both doses of plecanatide, 3 mg and 6 mg, met the primary endpoint of the proportion of patients in the intent-to-treat population who were durable overall responders versus placebo during the 12-week treatment period. Specifically, the results were: 3 mg arm: 21.0%; 6 mg arm: 19.5%; placebo: 10.2% (p<0.001).
- The durable overall responder endpoint is the current FDA metric for approval for CIC. Plecanatide would be the first drug cleared under this more stringent criterion.
- Plecanatide is an analog of uroguanylin, a gastrointestinal hormone produced in the small intestine that plays a key role in the normal functioning of the digestive tract.
- The company intends to file an New Drug Application (NDA) with the FDA in Q4.
Synergy Pharma's plecanatide successful in late-stage trial; shares up 50% premarket
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SGYP-OLD | - | - |
Synergy Pharmaceuticals, Inc. |